Discovery of a novel series of peroxisome proliferator-activated receptor α/γ dual agonists for the treatment of type 2 diabetes and dyslipidemia

Journal of Medicinal Chemistry

Volumn 48, Issue 7, 2005, Pages 2262-2265

  Liu, Kun ^a   Xu, Libo ^a   Berger, Joel P ^a   MacNaul, Karen L ^a   Zhou, Gauchao ^a   Doebber, Thomas W ^a   Forrest, Michael J ^a   Moller, David E ^a   Jones, A Brian ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(5,7 DIPROPYL 3 TRIFLUOROMETHYL)BENZISOXAZOL 6 YLOXY] 2 METHYLPROPIONIC ACID; FENOFIBRATE; FENOFIBRIC ACID; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; GLUCOSE; LIPID; MANDELIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROPIONIC ACID DERIVATIVE; ROSIGLITAZONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DYSLIPIDEMIA; EDEMA; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; WEIGHT GAIN;

3T3-L1 CELLS; ANIMALS; ANTILIPEMIC AGENTS; BLOOD GLUCOSE; CARRIER PROTEINS; CERCOPITHECUS AETHIOPS; CHOLESTEROL; COS CELLS; DIABETES MELLITUS, TYPE 2; DOGS; FATTY ACID-BINDING PROTEINS; HUMANS; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; ISOXAZOLES; MICE; MICE, OBESE; PPAR ALPHA; PPAR GAMMA; PROPIONIC ACIDS; RADIOLIGAND ASSAY; RNA, MESSENGER; STRUCTURE-ACTIVITY RELATIONSHIP; TRANS-ACTIVATION (GENETICS); TRIGLYCERIDES; WEIGHT GAIN;

EID: 17144375265     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm048993p     Document Type: Article

References (25)

1. (a) Kopelman, P. G.; Hitman, G. A. Diabetes. Exploding type II. Lancet 1998, 352 (Suppl 4), SIV5.
2. (b) Amos, A. F.; McCarthy, D. J.; Zimmet, P. The rising global burden of diabetes and its complications: estimates and projections by 2010. Diabet. Med. 1997, 14 (Suppl 5), S5-S85.
3. Haffner, S. M.; Lehto, S.; Ronnemaa, T.; Pyorala, K.; Laakso, M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with or without prior myocardial infarction. N. Eng. J. Med. 1998, 339, 229-234.
4. UKPDS. UK prospective diabetes study 33: intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications with type 2 diabetes. Lancet 1998, 352, 837-853.
5. Willson, T. M.; Brown, P. J.; Sternbach, D. D.; Henke, B. R. The PPARs: from orphan receptor to drug discovery J. Med. Chem. 2000, 43, 527-550.
6. Nuclear Receptors Nomenclature Committee, 1999. A unified nomenclature system for the nuclear receptor superfamily. Cell 1999, 97, 161-163.
7. Kersten, S.; Desvergne, B.; Wahli, W. Roles of PPARs in health and disease. Nature 2000, 405, 421-424.
8. (a) Berger, J.; Bailey, P.; Biswas, C.; Cullinan, C. A.; Doebber, T. W.; Hayes, N. S.; Saperstein, R.; Smith, R. G.; Leibowitz, M. D. Thiozolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-γ: binding and activation correlates with antidiabetic actions in db/db mice. Endocrinology 1996, 137, 4189-4195.
9. (b) Willson, T. M.; Cobb, J. E.; Cowan, D. J.; Wiethe, R. W.; Corea, I. D.; Prakash, S. R.; Beck, K. D.; Moore, L. B.; Kliver, S. A.; Lehman, J. M. The structure-activity relationship between peroxisome proliferator-activatied receptor γ agonism and the antihyperglycemic activity of thio-zolidinediones. J. Med. Chem. 1996, 39, 665-668.
10. Oaks, N. D.; Kennedy, C. J.; Jenkins, A. B.; Laybutt, D. R.; Chisholm, D. J.; Kraegen, E. W. A new antidiabtic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Dibetes 1994, 43, 1203-1210.
11. Schoonjans, K.; Staels, B.; Auwerx, J. Role of the peroxisome proliferators-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid Res. 1996, 37, 907-925.
12. (a) Teiner, G. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001, 357, 905-910.
13. (b) Rubins, H. B.; Robins, S. J. Conclutions from the VA-HIT study. Am. J. Cardiol. 2000, 86, 543-544.
14. (c) Rubins, H. B.; Robins, S. J.; Collins, D.; Fye, C. L.; Anderson, J. W.; Elam, M. B.; Faas, F. H.; Linares, E.; Schaefer, E. J.; Schectman, G.; Wilt, T. J.; Wittes, J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low Levels of high-density lipoprotein cholesterol. N. Eng. J. Med. 1999, 341, 410-418.
15. (a) Guerre-Millo; M., Gervois, P.; Raspe, E.; Madsen, L.; Poulain, P.; Derudas, B.; Herbert, J.; Winegar, D. A.; Wilson, T. M.; Fruchart, J.; Berge, R. K.; Staels, B. Peroxisome proliferators-activated receptor α activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem. 2000, 275, 16638-16642.
16. (b) Ye, J.-M.; Doyle, P.; Iglesias, M.; Watson, D.; Cooney, G.; Kraegen, E. Peroxosome proliferators activated receptor (PPAR)-α activation lowers muscle lipids and improve insulin sensitivity in high fat-fed rats. Diabetes 2001, 50, 411-417.
17. (c) Idzior-Walus, B.; Sieradzki, J.; Rostworowski, W.; Zdzienicka, A.; Kawalec, E.; Wojcik, J.; Zarnecki, A.; Blane, G. Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. Eur. J. Clin. Invest. 2000, 30, 871-878.
18. (d) Avogaro, A.; Miola, M.; Favaro, A.; Gottardo, L.; Pacini, G.; Manzato, E.; Zambon, S.; Sacerdoti, D.; de Kreutzenberg, S.; Piliego, T.; Tiengo, A.; Del Prato, S. Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. Eur. J. Clin. Invest. 2001, 31, 603-609.
19. Chaput, E.; Salafin, R.; Silvestre, M.; Edgar, A. D. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem. Biophy. Res. Commun. 2000, 271, 445-450.
20. Adams, A. D.; von Langen, D.; Dadiz, A.; Eibrecht, A.; MacNaul, K. L.; Berger, J. P.; Zhou, G.; Doebber, T. W.; Meurer, R.; Forrest, M.; Moller, D. E.; Jones, A. B. O-Arylmandelic acids as highly selective human PPAR α/γ dual agonists. Bioorg. Med. Chem. Lett. 2003, 13, 3185-3190.
21. For a similar approach, see: Brooks, D. A.; Etgen, G. J.; Rito, C. J.; Shuker, A. J.; Dominianni, S. J.; Warshawsky, A. M.; Ardecky, R.; Paterniti, J. R.; Tyhonas, J.; Karanewsky, D. S.; Kauffman, R. F.; Broderick, C. L.; Oldham, B. A.; Montrose-Rafizadeh, C.; Winneroski, L. L.; Faul, M. M.; McCarthy, J. R. Design and synthesis of 2-methyl-2-{4-[2-(5-methyl-2-aryloxazol-4-yl)ethoxy] phenoxy}propionic acids: a new class of dual PPARα/γ agonists. J. Med. Chem. 2001, 44, 2061-2064.
22. For the binding assay procedure, see: Adams, A. D.; Yuen, W.; Hu, Z.; Santini, C.; Jones, A. B.; MacNaul, K. L.; Berger, J. P.; Doebber, T. W.; Moller, D. E. Amphipathic 3-phenyl-7-propyl-benzisoxazoles; Human PPARγ, δ and α agonists. Bioorg. Med. Chem. Lett. 2003, 13, 931-936.
23. For the detailed procedures of the transactivation assay and db/db mice study, see: Berger, J.; Leibowitz, M. D.; Doebber, T. W.; Elbrecht, A.; Zhang, B.; Zhou, G.; Biswas, C.; Cullinan, C. A.; Hayes, N. S.; Li, Y.; Tanen, M.; Ventre, J.; Wu, M. S.; Berger, G. D.; Mosley, R.; Marquis, R.; Santini, C.; Sahoo, S. P.; Tolman, R. L.; Smith, R. G.; Moller, D. E. Novel peorxisome proliferator-activated receptor (PPAR) γ and PPARδ ligands produce distinct biological effects. J. Biol. Chem. 1999, 274, 6718-6725.
24. (a) Szalkowski, D.; White-Carrington, S.; Berger, J.; Zhang, B. Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-a on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology 1995, 136, 1474-1481.
25. (b) Berger, J.; Petro, A.; MacNaul, K.; Kelly, L.; Zhang, B.; Richards, K; Elbrecht, A.; Johnson, B.; Zhou, G.; Doebber, T.; Biswas, C.; Parikh, M.; Sharma, N.; Tanen, M.; Thompson, G.; Ventre, J.; Adams, A.; Mosley, R.; Surwit, R.; Moller, D. Distinct properties and advantages of a novel peroxisome proliferators-activated protein γ selective modulator. Mol. Endocrinol. 2003, 17, 662-676.